Book contents
- Frontmatter
- Contents
- CONTRIBUTORS
- PREFACE
- Chap. 1 CELL INJURY AND CELL DEATH
- Chap. 2 CLEAN AND ASEPTIC TECHNIQUE AT THE BEDSIDE
- Chap. 3 NEW ANTIMICROBIALS
- Chap. 4 IMMUNOMODULATORS AND THE “BIOLOGICS” IN CUTANEOUS EMERGENCIES
- Chap. 5 CRITICAL CARE: STUFF YOU REALLY, REALLY NEED TO KNOW
- Chap. 6 ACUTE SKIN FAILURE: CONCEPT, CAUSES, CONSEQUENCES, AND CARE
- Chap. 7 CUTANEOUS SYMPTOMS AND NEONATAL EMERGENCIES
- Chap. 8 NECROTIZING SOFT-TISSUE INFECTIONS, INCLUDING NECROTIZING FASCIITIS
- Chap. 9 LIFE-THREATENING BACTERIAL SKIN INFECTIONS
- Chap. 10 BACTEREMIA, SEPSIS, SEPTIC SHOCK, AND TOXIC SHOCK SYNDROME
- Chap. 11 STAPHYLOCOCCAL SCALDED SKIN SYNDROME
- Chap. 12 LIFE-THREATENING CUTANEOUS VIRAL DISEASES
- Chap. 13 LIFE-THREATENING CUTANEOUS FUNGAL AND PARASITIC DISEASES
- Chap. 14 LIFE-THREATENING STINGS, BITES, AND MARINE ENVENOMATIONS
- Chap. 15 SEVERE, ACUTE ADVERSE CUTANEOUS DRUG REACTIONS I: STEVENS–JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLYSIS
- Chap. 16 SEVERE, ACUTE ADVERSE CUTANEOUS DRUG REACTIONS II: DRESS SYNDROME AND SERUM SICKNESS-LIKE REACTION
- Chap. 17 SEVERE, ACUTE COMPLICATIONS OF DERMATOLOGIC THERAPIES
- Chap. 18 SEVERE, ACUTE ALLERGIC AND IMMUNOLOGICAL REACTIONS I: URTICARIA, ANGIOEDEMA, MASTOCYTOSIS, AND ANAPHYLAXIS
- Chap. 19 SEVERE, ACUTE ALLERGIC AND IMMUNOLOGICAL REACTIONS II: OTHER HYPERSENSITIVITIES AND IMMUNE DEFECTS, INCLUDING HIV
- Chap. 20 GRAFT VERSUS HOST DISEASE
- Chap. 21 ERYTHRODERMA/EXFOLIATIVE DERMATITIS
- Chap. 22 ACUTE, SEVERE BULLOUS DERMATOSES
- Chap. 23 EMERGENCY MANAGEMENT OF PURPURA AND VASCULITIS, INCLUDING PURPURA FULMINANS
- Chap. 24 EMERGENCY MANAGEMENT OF CONNECTIVE TISSUE DISORDERS AND THEIR COMPLICATIONS
- Chap. 25 SKIN SIGNS OF SYSTEMIC INFECTIONS
- Chap. 26 SKIN SIGNS OF SYSTEMIC NEOPLASTIC DISEASES AND PARANEOPLASTIC CUTANEOUS SYNDROMES
- Chap. 27 BURN INJURY
- Chap. 28 EMERGENCY DERMATOSES OF THE ANORECTAL REGIONS
- Chap. 29 EMERGENCY MANAGEMENT OF SEXUALLY TRANSMITTED DISEASES AND OTHER GENITOURETHRAL DISORDERS
- Chap. 30 EMERGENCY MANAGEMENT OF ENVIRONMENTAL SKIN DISORDERS: HEAT, COLD, ULTRAVIOLET LIGHT INJURIES
- Chap. 31 ENDOCRINOLOGIC EMERGENCIES IN DERMATOLOGY
- Chap. 32 EMERGENCY MANAGEMENT OF SKIN TORTURE AND SELF-INFLICTED DERMATOSES
- Chap. 33 SKIN SIGNS OF POISONING
- Chap. 34 DISASTER PLANNING: MASS CASUALTY MANAGEMENT
- Chap. 35 CATASTROPHES IN COSMETIC PROCEDURES
- Chap. 36 LIFE-THREATENING DERMATOSES IN TRAVELERS
- Index
- References
Chap. 17 - SEVERE, ACUTE COMPLICATIONS OF DERMATOLOGIC THERAPIES
Published online by Cambridge University Press: 07 September 2011
- Frontmatter
- Contents
- CONTRIBUTORS
- PREFACE
- Chap. 1 CELL INJURY AND CELL DEATH
- Chap. 2 CLEAN AND ASEPTIC TECHNIQUE AT THE BEDSIDE
- Chap. 3 NEW ANTIMICROBIALS
- Chap. 4 IMMUNOMODULATORS AND THE “BIOLOGICS” IN CUTANEOUS EMERGENCIES
- Chap. 5 CRITICAL CARE: STUFF YOU REALLY, REALLY NEED TO KNOW
- Chap. 6 ACUTE SKIN FAILURE: CONCEPT, CAUSES, CONSEQUENCES, AND CARE
- Chap. 7 CUTANEOUS SYMPTOMS AND NEONATAL EMERGENCIES
- Chap. 8 NECROTIZING SOFT-TISSUE INFECTIONS, INCLUDING NECROTIZING FASCIITIS
- Chap. 9 LIFE-THREATENING BACTERIAL SKIN INFECTIONS
- Chap. 10 BACTEREMIA, SEPSIS, SEPTIC SHOCK, AND TOXIC SHOCK SYNDROME
- Chap. 11 STAPHYLOCOCCAL SCALDED SKIN SYNDROME
- Chap. 12 LIFE-THREATENING CUTANEOUS VIRAL DISEASES
- Chap. 13 LIFE-THREATENING CUTANEOUS FUNGAL AND PARASITIC DISEASES
- Chap. 14 LIFE-THREATENING STINGS, BITES, AND MARINE ENVENOMATIONS
- Chap. 15 SEVERE, ACUTE ADVERSE CUTANEOUS DRUG REACTIONS I: STEVENS–JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLYSIS
- Chap. 16 SEVERE, ACUTE ADVERSE CUTANEOUS DRUG REACTIONS II: DRESS SYNDROME AND SERUM SICKNESS-LIKE REACTION
- Chap. 17 SEVERE, ACUTE COMPLICATIONS OF DERMATOLOGIC THERAPIES
- Chap. 18 SEVERE, ACUTE ALLERGIC AND IMMUNOLOGICAL REACTIONS I: URTICARIA, ANGIOEDEMA, MASTOCYTOSIS, AND ANAPHYLAXIS
- Chap. 19 SEVERE, ACUTE ALLERGIC AND IMMUNOLOGICAL REACTIONS II: OTHER HYPERSENSITIVITIES AND IMMUNE DEFECTS, INCLUDING HIV
- Chap. 20 GRAFT VERSUS HOST DISEASE
- Chap. 21 ERYTHRODERMA/EXFOLIATIVE DERMATITIS
- Chap. 22 ACUTE, SEVERE BULLOUS DERMATOSES
- Chap. 23 EMERGENCY MANAGEMENT OF PURPURA AND VASCULITIS, INCLUDING PURPURA FULMINANS
- Chap. 24 EMERGENCY MANAGEMENT OF CONNECTIVE TISSUE DISORDERS AND THEIR COMPLICATIONS
- Chap. 25 SKIN SIGNS OF SYSTEMIC INFECTIONS
- Chap. 26 SKIN SIGNS OF SYSTEMIC NEOPLASTIC DISEASES AND PARANEOPLASTIC CUTANEOUS SYNDROMES
- Chap. 27 BURN INJURY
- Chap. 28 EMERGENCY DERMATOSES OF THE ANORECTAL REGIONS
- Chap. 29 EMERGENCY MANAGEMENT OF SEXUALLY TRANSMITTED DISEASES AND OTHER GENITOURETHRAL DISORDERS
- Chap. 30 EMERGENCY MANAGEMENT OF ENVIRONMENTAL SKIN DISORDERS: HEAT, COLD, ULTRAVIOLET LIGHT INJURIES
- Chap. 31 ENDOCRINOLOGIC EMERGENCIES IN DERMATOLOGY
- Chap. 32 EMERGENCY MANAGEMENT OF SKIN TORTURE AND SELF-INFLICTED DERMATOSES
- Chap. 33 SKIN SIGNS OF POISONING
- Chap. 34 DISASTER PLANNING: MASS CASUALTY MANAGEMENT
- Chap. 35 CATASTROPHES IN COSMETIC PROCEDURES
- Chap. 36 LIFE-THREATENING DERMATOSES IN TRAVELERS
- Index
- References
Summary
ALTHOUGH PHYSICIANS from other specialties, like the population at large, still consider cutaneous maladies as being mainly aesthetic, skin deep, and insignificant, they are generally aware that treating these diseases often requires a variety of potent systemic drugs and not only topical treatments. These powerful medications may cause many adverse reactions, some of them severe, acute, or even life threatening.
“There are no really ‘safe’ biologically active drugs. There are only ‘safe’ physicians.” A “safe” physician must, first and foremost, be well informed about adverse reactions at the time of prescribing a drug, during the follow-up period, and especially when one of these rare catastrophes suddenly occurs. Because the diversity of severe adverse reactions to dermatologic therapies is almost endless, we focus on new drugs and the less known adverse effects.
TARGETED IMMUNE MODULATORS/BIOLOGICS
Targeted immune modulators (TIMs) – commonly referred to as biological response modifiers or simply “biologics” – are a relatively new category of medications used in the treatment of certain types of immunologic and inflammatory diseases, including dermatologic diseases, most notably psoriasis.
Overall, TIMs appear to have a good tolerability profile, although some rare but acute serious adverse events, such as infections, hematologic events, neurologic events, infusion reactions, congestive heart failure, nephrotic syndrome, and others, are of concern. The following sections describe adverse events associated with TIMs.
- Type
- Chapter
- Information
- Emergency Dermatology , pp. 168 - 177Publisher: Cambridge University PressPrint publication year: 2011